Table 1. Analysis of factors related to PDX models.
| Factors | PDX status | |||
|---|---|---|---|---|
| Failure (%) | Success (%) | p-value | ||
| Age (years) | <60 | 43 (67.2%) | 14 (73.7%) | 0.592 |
| ≥60 | 21 (32.8%) | 5 (26.3%) | ||
| T stage | -T1 | 34 (56.7%) | 5 (26.3%) | 0.038 |
| T2 | 22 (36.7%) | 10 (52.6%) | ||
| T3-T4 | 4 (6.7%) | 4 (21.1%) | ||
| Nodal status | Negative | 40 (65.6%) | 8 (47.1%) | 0.165 |
| Positive | 21 (34.4%) | 9 (52.9%) | ||
| Histologic grade | I/II | 33 (56.9%) | 3 (15.8%) | 0.002 |
| III | 25 (43.1%) | 16 (84.2%) | ||
| ER | Negative | 51 (79.7%) | 19 (100.0%) | 0.032 |
| Positive | 13 (20.3%) | 0 (0.0%) | ||
| PR | Negative | 55 (85.9%) | 19 (100.0%) | 0.083 |
| Positive | 9 (14.1%) | 0 (0.0%) | ||
| HER2 | Negative | 56 (87.5%) | 19 (100.0%) | 0.105 |
| Positive | 8 (12.5%) | 0 (0.0%) | ||
| Ki67 (%, n = 79) | <39 (n = 41) | 38 (62.3%) | 3 (16.7%) | 0.001 |
| ≥39 (n = 38) | 23 (37.7%) | 15 (83.3%) | ||
| BRCA mutation | Absent | 61(96.9%) | 15(78.9%) | 0.005 |
| Present | 2(3.1%) | 4(21.1%) | ||
| Survival status | Live | 62(96.9%) | 15(78.9%) | 0.008 |
| Death | 2(3.1%) | 4(21.1%) | ||
| Aggressive diseases* | Absent | 54 (87.5%) | 10 (63.2%) | 0.004 |
| Present | 10 (12.5%) | 9 (36.8%) | ||
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; Ki67: cell proliferation index
* Aggressive diseases were considered to be progressive diseases during neoadjuvant chemotherapy, recurrent, and metastatic disease